期刊
CARDIOVASCULAR DRUGS AND THERAPY
卷 31, 期 1, 页码 53-61出版社
SPRINGER
DOI: 10.1007/s10557-016-6691-0
关键词
Acute myocardial infarction; STelevation myocardial infarction; Myocardial infarct size reduction; Beta blockade; Adenosine; Hypothermia
资金
- Stealth Biotherapeutics
The size of the myocardial infarction remains an important therapeutic target, because heart attack size correlates with mortality and heart failure. In this era, myocardial infarct size is reduced primarily by timely reperfusion of the infarct related coronary artery. Whereas numerous pre-clinical studies have shown that certain pharmacologic agents and therapeutic maneuvers reduce myocardial infarction size greater than reperfusion alone, very few of these therapies have translated to successful clinical trials or standard clinical use. In this review we discuss both the recent successes as well as recent disappointments, and describe some of the newer potential therapies from the preclinical literature that have not yet been tested in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据